A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
Condition: Melanoma Interventions: Drug: tunlametinib; Drug: paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin Sponsor: Shanghai Kechow Pharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Conditions: Choroidal Melanoma; Indeterminate Lesions; Uveal Melanoma; Ocular Melanoma Interventions: Drug: Belzupacap Sarotalocan; Device: Suprachoroidal Microinjector; Device: Infrared Laser; Device: Sham Infrared Laser; Device: Sham Microinjector; Drug: Sham Treatment Sponsor: Aura Biosciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 23, 2023 Category: Research Source Type: clinical trials
IDEAYA Announces First-Patient-In for Company-Sponsored Phase 2 Clinical Trial Evaluating Darovasertib in (Neo)Adjuvant Uveal Melanoma
Dosed a first patient in a company-sponsored global Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM)
Preliminary clinical activity observed in primary UM, including tumor shrinkage... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - August 16, 2023 Category: Pharmaceuticals Source Type: clinical trials
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
Condition: Melanoma (Skin) Interventions: Drug: BCD-201; Drug: Keytruda Sponsor: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Condition: Metastatic Uveal Melanoma Interventions: Drug: IDE196; Drug: Crizotinib; Drug: Pembrolizumab; Drug: Ipilimumab; Drug: Nivolumab; Drug: Dacarbazine Sponsor: IDEAYA Biosciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma
Condition: Melanoma (Skin) Interventions: Drug: BCD-201; Drug: Keytruda Sponsor: Biocad Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 14, 2023 Category: Research Source Type: clinical trials
